Lichuankang Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a bulk active substance supplied for further pharmaceutical manufacture. It is not a finished veterinary medicinal product and is not intended for direct administration to animals. The material is released against a certificate of analysis that lists active moiety identity, assay, related substances, residual solvents, elemental impurities, moisture, particle size distribution, and microbial quality. Because the product is trade-specific, no official pharmacopoeial monograph under the exact name Lichuankang Powder is assumed; the active moiety and impurity profile must be verified from the approved drug master file or marketing authorisation dossier. The manufacturer may issue separate internal material codes for standard, micronized, and sterile-ready powder grades. These model designations refer to particle-size and microbial-control levels rather than different chemical entities.

Which Physical and Microbiological Quality Attributes Govern Use Across All Seven Dosage Forms?

Control of particle size distribution, bulk density, tapped density, flow index, moisture content, and crystallinity determines whether the same lot can be processed into directly compressed tablets, filled into hard gelatin capsules, dry-mixed into premixes, or dissolved into injection-grade solutions. Particle size is commonly measured by laser diffraction according to ISO 13320:2020, and the D10, D50, and D90 values are used to set milling targets. For the powder to pass through a 0.45 mm sieve in a solid oral dosage line, the D90 is typically controlled below 850 µm; many tableting operations require a D90 below 250 µm to reduce segregation. Powder flow is characterised by compressibility index and Hausner ratio according to Ph. Eur. 2.9.36. A compressibility index between 5% and 15% is generally considered acceptable for direct compression. Values above 25% indicate poor flow and usually exclude direct compression without granulation.

Microbial quality is also critical because the powder is non-sterile bulk material. For oral powders and premixes, acceptance criteria are commonly aligned with Ph. Eur. 5.1.4 or USP general chapter 1111. The absence of Escherichia coli and Salmonella is a standard release requirement for many veterinary oral products. For injectable applications, the powder is not acceptable for direct use unless the downstream process includes sterilizing-grade filtration or terminal sterilisation. The values in Table 1 are representative general controls for a concentrated veterinary API powder, not product-specific release limits; the approved specification remains the controlling document.

For tablet and capsule manufacture, Lichuankang Powder is normally discharged from validated bulk containers under material handling controls consistent with 21 CFR 211 and blended with fillers, disintegrants, and lubricants. Direct compression is rarely appropriate for API powders with an angle of repose above 40°; instead, wet granulation or roller compaction is specified. On a rotary tablet press operating at 30–80 rpm, precompression force is commonly adjusted to 5–15 kN depending on tablet diameter and powder density. If moisture exceeds 1.0%, the compression process may produce sticking, picking, or weight variation. Blend uniformity is confirmed by sampling at 10 locations and testing content uniformity according to Ph. Eur. 2.9.40 or USP general chapter 905. Capsule filling on dosator or tamping machines requires a powder bed with consistent bulk density to avoid weight variation exceeding ±5% of target fill weight. Blending with magnesium stearate for more than 5 min can reduce tablet tensile strength and delay dissolution because of hydrophobic film formation; therefore, lubricant type, concentration, and blending time must be optimised. Tablet hardness is measured by Ph. Eur. 2.9.8, friability by Ph. Eur. 2.9.7, and disintegration by Ph. Eur. 2.9.1.

When the API Is Converted into Injections or Soluble Solutions, Sterility Strategy Changes

Injectable and soluble solution dosage forms require a different quality gate. The bulk powder is dissolved in water for injection or a compatible cosolvent system, pH-adjusted, and filtered before filling. The solution is passed through a 0.22 µm sterilizing-grade membrane filter; if the active substance is heat-labile, the entire manufacturing line must operate as an aseptic process under EU GMP Annex 1 and PIC/S PE 009-17. Terminal sterilisation at 121 °C for 15 min may be used only when the API demonstrates no degradation beyond identification or assay limits. The loading of active substance into the injection vehicle must be confirmed by assay and related substances after 24 h and 48 h hold times. The formulation should be tested for sub-visible particles according to Ph. Eur. 2.9.19 or USP general chapter 788, and visible particles according to Ph. Eur. 2.9.20.

For soluble powders and drinking-water formulations, the dissolution profile is evaluated in hard water and soft water at 5 °C and 25 °C. Water hardness above 300 ppm as CaCO₃ can reduce solubility; therefore, chelating agents or pH buffers may be required. The powder should be sieved to avoid undissolved particles that could block nipple drinkers or metering pumps. A 0.150 mm sieve is common for continuous medication systems. A target dissolution time of ≤30 min is typically used for soluble powders, although the acceptance limit must be justified by the intended dosing regimen. The solution should be protected from light if photodegradation is observed during the stress studies required by VICH GL3.

Premix, Granule, and Powder Carriers in Feed and Drinking Water Applications

When Lichuankang Powder is incorporated into premixes and granules, the main processing risks are segregation, electrostatic adhesion, and moisture-induced caking. Premix manufacture generally uses a ribbon blender or double-cone blender with a fill volume of 60–70% of gross capacity; the API is added by geometric dilution onto a carrier such as lactose monohydrate, dextrose, or calcium carbonate. Homogeneity is assessed by taking 10 thief samples and calculating a coefficient of variation below 5% for the active assay. Sampling and analysis plans for animal feed premixes are aligned with ISO 6497:2002; the sampling plan should cover at least 10 locations across the blender. If mineral carriers are used, electrostatic charge may be controlled by grounding and by maintaining relative humidity between 40% and 60%.

Granulation may be performed in a high-shear mixer or fluidized-bed granulator. A binder solution with viscosity between 100 mPa·s and 500 mPa·s is sprayed at a rate that avoids overwetting; endpoint is commonly detected by impeller power consumption or near-infrared moisture sensors. Scale-up from 25 L to 600 L high-shear granulators requires matching impeller tip speed, spray rate, and wet mass density. If impeller power increases more than 20% from the dry mix baseline, overwetting may occur. If the product is intended for oral powder use, particle size is adjusted to pass a 0.500 mm sieve, and the final moisture content is kept below 5% to reduce mold growth.

Differentiation from Competing Veterinary APIs Defined by Solubility, Stability, and Milling Control

Compared with finished premix or feed-additive products that contain carriers, Lichuankang Powder is an undiluted active substance, which transfers the burden of blend uniformity, dissolution, and stability control to the downstream formulator. This distinguishes it from commercial formulations that may include wetting agents, solubilizers, or stabilizers. The degree of milling is a critical differentiator: micronized grades may be required for injectable suspensions, while larger-particle grades may be preferred for dry premix to minimise dust formation. Thermal stability differences must be established by forced degradation and stress studies. If the powder is compared with another active substance, the degradation pathways should be profiled by HPLC peak purity or LC-MS. The absence of a monograph under the trade name Lichuankang means that equivalence must be shown by full characterisation rather than reliance on a general monograph.

Operational boundaries must be confirmed before the powder is used in a specific line. Avoid combining the powder with strong oxidizing agents unless compatibility has been demonstrated. If the material is hygroscopic, pre-drying should be carried out only when indicated by sorption data; uncontrolled drying may change crystal form and dissolution rate. Containers should be closed immediately after use, and the powder should be stored away from direct sunlight and at the temperature stated on the label. Formal stability studies for the bulk powder and each finished dosage form follow VICH GL3. Long-term storage conditions are commonly 25 °C ± 2 °C/60% RH ± 5% RH, and accelerated conditions are 40 °C ± 2 °C/75% RH ± 5% RH. Because the trade-name product may not have a published pharmacopoeial monograph, batch-to-batch equivalence should be verified by comparing identity, assay, impurities, particle size distribution, and residual solvents against the filed drug master file or marketing authorisation dossier. Published data for this specific commercial presentation is limited; therefore, the certificate of analysis and approved specification are the controlling documents for all seven intended routes of formulation.